SpliSense

SpliSense is developing antisense oligonucleotide-based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound that can treat lung disease in cystic fibrosis patients with specific splicing mutations. It is also developing a targeted modulation approach to correct CFTR splicing transcript patterns based on the specific mutations carried.